Eli Lilly & Co., headquartered in Indianapolis, employs 43,000 staff and develops various pharmaceutical products, including diabetes, oncology, immunology, and neuroscience therapies, alongside radiopharmaceuticals through its subsidiary POINT Biopharma. The company manufactures and distributes products in the U.S., Europe, and Asia.
Lilly(Eli) & Company (LLY) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Lilly(Eli) & Company's actual EPS was $3.34, beating the estimate of $3.05 per share, resulting in a 9.38% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
